INTRODUCTION
Theophylline and related xanthines have been used in the treatment of diseases of the airways for over 50 years and remain widely prescribed drugs world-wide for the treatment of bronchial asthma.1-3 The therapeutic effectiveness of this class of drugs was traditionally thought to be derived from their ability to produce bronchodilatation.
However, it is now becoming increasingly apparent that theophylline, in particular, has both immunomodulatory and anti-inflammatory activity. Although theophylline has been used extensively in the treatment of asthma, its molecular mechanism(s) is not clear. Several putative mechanisms of action have been suggested to explain the therapeutic effectiveness of theophylline and related xanthines.
One mechanism that has been proposed is that theophylline, through non-selective phosphodiesterase (PDE) inhibition, raises intracellular cyclic 3',5'-adenosine monophosphate (cAMP) and cyclic 3',5'-guanosine monophosphate (cGMP) levels resulting in relaxation of airway smooth muscle and inhibition of inflammatory cell activation. Theophylline is a relatively weak inhibitor of PDE, although there is evidence to suggest that PDE activity is elevated in leukocytes from patients with atopic disease (atopic dermatitis, asthma, allergic rhinitis), 4 and thus an altered responsiveness to PDE inhibitors may partly explain the mechanism of action of theophylline.
Seven gene families of the PDE enzyme have so far been defined, each of which can be distinguished by a variety of criteria including their substrate specificity, sensitivity to selective inhibitors and the effect of allosteric modulators. 5 The type IV isoenzyme appears to be the main isoenzyme of PDE inflammatory cells, although it exists together with the type III isoenzyme in T cells. 6 It is becoming increasingly apparent that theophylline possesses anti-inflammatory and immunomodulatory actions7-9 that may well contribute to the clinical efficacy of this drug in the treatment of asthma. Type III and IV PDE isoenzymes have been characterized in T cells22,23 and selective inhibitors of the type III and IV PDE isoenzyme have been shown to inhibit phytohaemagglutinin (PHA)-stimulated human24 and murine25 T cell proliferation. In a study using rat thymocyte cells, type III, IV and V inhibitors were examined for their ability to inhibit the concavaline A-stimulated pro- lation. In another study, theophylline was found to inhibit the release of ECP and reactive oxygen species from highly purified blood eosinophils47 with a potency nearly identical to that for inhibition of PDE type IV activity. Superoxide anions and arachidonic acid derivatives are generated by leukocytes and it has been suggested that they may contribute to airway injury, oedema and smooth muscle contraction seen in asthma.48 In one study by Yukawa et al., concentrations of theophylline which cover the therapeutic range (10-6-10-5 mmol), significantly potentiated opsonized zymosan-induced O2 generation from isolated guinea pig and human eosinophils, whereas at high concentrations there was a significant inhibition of the release.49 In another study, therapeutic concentrations of theothe respiratory burst and also arachidonic acid metabolite generation induced by chemotactic peptides such as fMLP and the calcium ionophore, A23187.50,51
EFFECTS OF THEOPHYLLINE AND SELECTIVE PDE ISOENZYME INHIBITORS ON CELLS INVOLVED I N ASTHMA
The type IV PDE isoenzyme is the only PDE isoenzyme which has been characterized in guinea pig eosinophils52 and a number of studies have examined the effect of isoenzyme selective inhibitors on the respiratory burst and the release of cationic proteins from guinea pig eosinophils.
The The late asthmatic reaction (LAR) to allergen exposure has commonly been used as a model of airway inflammation and this model has been used to evaluate anti-inflammatory drugs. 
